KalVista Pharmaceuticals provides clinical update on KVD900
KalVista reported that KVD900 displays a profile well-suited for use as an on-demand therapy for HAE attacks, with a combination of rapid and high uptake into the plasma resulting in fast and strong inhibition of plasma kallikrein. November 12, 2018